Go Deep
Brooks Laboratories Limited
Brooks Laboratories Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Sep 2026 | 26,616 | 12.6 | 1.36 | 0.07 | 56.51 |
| Oct 2026 | 26,494 | 12.2 | 1.32 | 0.07 | 54.80 |
| Oct 2026 | 24,484 | 15.6 | 1.68 | 0.07 | 70.13 |
Brooks Laboratories Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 229,608,000.0 | 202,095,000.0 | 165,663,000.0 | 234,507,000.0 |
| Net Profit | -17,869,000.0 | 15,230,000.0 | 54,988,000.0 | 79,769,000.0 |
| EPS | -0.6 | 0.5 | 1.9 | 2.7 |
Brooks Laboratories Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 853,755,000.0 | 821,856,000.0 | 790,116,000.0 | 624,804,000.0 | — |
| Net Profit | 245,835,000.0 | -99,670,000.0 | -195,916,000.0 | -208,919,000.0 | — |
| EPS | 8.3 | -3.7 | -7.7 | -12.6 | — |
Brooks Laboratories Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 1,481,739,000.0 | 1,236,942,000.0 | 904,455,000.0 | 1,095,973,000.0 | — |
| Total Liabilities | 255,168,000.0 | 255,899,000.0 | 248,602,000.0 | 356,440,000.0 | — |
| Total Equity | 1,226,571,000.0 | 981,043,000.0 | 655,853,000.0 | 739,533,000.0 | — |
Owes vs Owns
Brooks Laboratories Limited owed ₹0.17 for every ₹1 it owned in Mar 2026, down from ₹0.33 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.17× | 0.21× | 0.27× | 0.33× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Brooks Laboratories Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 4.4%Receivables 10.9%Inventory 7.4%Fixed assets (tangible) 11.0%Long-term investments 62.3%Other assets 4.0%
How it's funded — Mar 2026
Short-term debt 4.1%Long-term debt 0.8%Payables 7.7%Other liabilities 4.6%Shareholders' equity 82.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 6.6 | 0.0 | 0.1 | 0.0 |
| Receivables | 16.1 | 20.0 | 16.3 | 12.8 |
| Inventory | 11.0 | 9.2 | 9.6 | 11.3 |
| Fixed assets (tangible) | 16.3 | 14.2 | 13.6 | 14.8 |
| Intangible assets | 0.0 | 0.0 | 0.1 | 0.2 |
| Long-term investments | 92.3 | 73.5 | 42.8 | 64.0 |
| Other assets | 5.9 | 6.7 | 7.9 | 6.5 |
| Liabilities & equity | ||||
| Short-term debt | 6.1 | 5.9 | 5.0 | 5.7 |
| Long-term debt | 1.2 | 0.1 | 0.0 | 0.0 |
| Payables | 11.4 | 13.6 | 15.4 | 23.4 |
| Other liabilities | 6.8 | 5.9 | 4.4 | 6.6 |
| Shareholders' equity | 122.7 | 98.1 | 65.6 | 74.0 |
| Net tangible assets | 122.7 | 98.1 | 65.5 | 73.8 |
Brooks Laboratories Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 92,934,000.0 | 26,263,000.0 | -98,008,000.0 | -144,902,000.0 | — |
| Investing Activities | -29,198,000.0 | -451,352,000.0 | 1,822,000.0 | 4,949,000.0 | — |
| Financing Activities | 1,709,000.0 | 424,268,000.0 | 97,209,000.0 | 114,136,000.0 | — |